首个治疗骨巨细胞瘤的药物地舒单抗在国内上市了吗？

It is a fully humanized immunoglobulin (Ig) G2 monoclonal antibody prepared using DNA recombinant technology. Its target is receptor activator of nuclear factor-κB ligand (RANKL). Recent studies have shown that the nuclear factor-κB receptor activator/nuclear factor-κB receptor activator ligand/osteoprotegerin (RANK/RANKL/OPG) system plays a key role in the maturation and activation of osteoclasts, maintains bone metabolic balance, and is also involved in the occurrence of SRE in malignant tumor bone metastases. It is these basic studies that provide new targets for the development of drugs to prevent SRE from bone metastasis of malignant tumors. New drug development ideas depend on progress in basic medical research.

Following the approval of denosumab by the US Food and Drug Administration (FDA) in November 2010, in July 2011, the European Medicines Agency (EMA) also officially approved denosumab for the prevention of SRE in patients with bone metastases from solid tumors. Desosumab is a fully humanized immunoglobulin (Ig) G2 monoclonal antibody prepared using recombinant DNA technology. Its target is receptor activator of nuclear factor-κB ligand (RANKL). The State Food and Drug Administration conditionally approved the listing of denosumab on May 21, 2019. As a new drug, the domestic price of denosumab can be said to be quite high. The domestic price of denosumab with a specification of 120mg/1.7ml bottle/box is 5298$, which makes it prohibitive for many patients.

Fortunately, according to Medical Companion Travel, we learned that the price of 120mg produced by Amgen in the United States is about $3,000. If you need to buy denosumab, you can choose to go abroad to buy the original drug or buy it at home. You can also choose domestic reliable overseas medical institutions (such as Medical Companion Travel) to purchase it. It is 100% authentic and can be shipped directly to your home.